Original price was: ₹4,485.94.₹2,200.00Current price is: ₹2,200.00.
Lenvakast 4 mg Capsule acts as an oral inhibitor for receptor tyrosine kinases. Doctors prescribe it mainly for thyroid cancer treatment. This applies especially in advanced cases. It also helps when the disease fails to respond to other options.
Salt/Formula: Lenvatinib (4mg)
Manufacturer: Aprazer Healthcare Pvt. Ltd.
Dosage: 4mg
Lenvakast 4 mg Capsule serves as a treatment option for several serious conditions.
It targets certain advanced forms of thyroid cancer in patients who need targeted therapy.
The medication also addresses advanced liver cancer, helping to manage its progression over time.
For kidney cancer, it specifically treats renal cell carcinoma in more severe cases.
Endometrial cancer falls under its indications as well, providing support in advanced stages.
Follow your doctor’s exact instructions for this medication. Take it in the dose they recommend and for the full time they specify.
Follow your doctor’s exact instructions for this medication. Take it in the dose they recommend and for the full time they specify.
Most side effects tend to be pretty mild overall. They usually do not call for any kind of medical attention. These effects often get better as your body starts adjusting to the medication. Still, if certain side effects keep going or start to worry you,
reach out to your doctor.
Common ones can involve vomiting,
a drop in appetite,
some joint pain,
sores inside the mouth,
nausea,
and low blood pressure,
which doctors call hypotension.
Lenvakast 4 mg Capsule includes Lenvatinib as the key active ingredient. This substance works as a tyrosine kinase inhibitor. Doctors prescribe it mainly for progressive or advanced thyroid cancer cases. They turn to it especially when radioactive iodine therapy stops being effective. The capsule also treats unresectable liver cancer in patients. These are individuals who have not yet received any prior systemic therapy.
Select at least 2 products
to compare
Reviews
There are no reviews yet.